EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Favorable Outcome With Eculizumab in Hemolytic Uremic Syndrome Presenting With Severe Neurological Complications: A Case Report

Maryam Zaitoun iD, Abdulkarim Alanazi iD, Tasneem Kattash iD, Abdullah Wali, Amna Abdelbagi, Sawsan Al Batati iD, Hassan Faqeehi, Saeed Al Zabali iD

Case Reports in Nephrology · 2026-01 · 2026 (1)

DOI: 10.1155/crin/8844271 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Nephrology, online erschienen am 03.08.2026. Verfasst von Maryam Zaitoun und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, alfaisal.edu. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Thrombotic microangiopathies (TMAs) are a group of rare, life‐threatening disorders characterized by a classic triad of MAHA, severe thrombocytopenia, and ischemic tissue injury. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are the main types of TMAs. Based on the cause, HUS can be classified as typical or atypical. Case Presentation We present the case of a 4‐year‐old child referred to King Fahad Medical City in Riyadh, Saudi Arabia, with complaints of bloody diarrhea, vomiting, and fever. The condition progressed to altered consciousness, seizures, and quadriparesis.

Result

Upon admission, the patient received plasma infusion and underwent peritoneal dialysis. Eculizumab therapy was initiated 1 week after the presentation. Hematological and renal parameters improved rapidly, but neurological recovery was gradual, with significant progress observed over 6 years of follow‐up.

Conclusion

This case highlights that severe neurological manifestations can be an initial feature of HUS, not just TTP. Eculizumab was effective and life‐saving in pediatric patients with TMA and severe neurological involvement, though CNS recovery may take years.

Schlagwörter

Stichwörter der Autor:innen

CNS involvementcomplement-mediated TMAhemolytic uremic syndrome (HUS)infection-associated HUS (STEC-HUS)seizures

Autor:innen und Institutionen

  • College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, alfaisal.edu.
  • Pediatric Nephrology Department, Children's Hospital, King Fahad Medical City, Riyadh, Saudi Arabia, kfmc.med.sa.

ORCID-Profile: Maryam Zaitoun, Abdulkarim Alanazi, Tasneem Kattash, Sawsan Al Batati, Saeed Al Zabali

Zitieren

APA

Zaitoun, M., Alanazi, A., Kattash, T., Wali, A., Abdelbagi, A., Batati, S. A., Faqeehi, H., & Zabali, S. A. (2026). Favorable Outcome With Eculizumab in Hemolytic Uremic Syndrome Presenting With Severe Neurological Complications: A Case Report. Case Reports in Nephrology, 2026(1). https://doi.org/10.1155/crin/8844271

Vancouver

Zaitoun M, Alanazi A, Kattash T, Wali A, Abdelbagi A, Batati SA, et al. Favorable Outcome With Eculizumab in Hemolytic Uremic Syndrome Presenting With Severe Neurological Complications: A Case Report. Case Reports in Nephrology. 2026;2026(1). doi:10.1155/crin/8844271

BibTeX
@article{Zaitoun2026,
  author = {Zaitoun, Maryam and Alanazi, Abdulkarim and Kattash, Tasneem and Wali, Abdullah and Abdelbagi, Amna and Batati, Sawsan Al and Faqeehi, Hassan and Zabali, Saeed Al},
  title = {Favorable Outcome With Eculizumab in Hemolytic Uremic Syndrome Presenting With Severe Neurological Complications: A Case Report},
  journal = {Case Reports in Nephrology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crin/8844271}
}
Kostenlos starten →